Equities

Taiko Pharmaceutical Co Ltd

4574:TYO

Taiko Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)483.00
  • Today's Change19.00 / 4.09%
  • Shares traded667.20k
  • 1 Year change+40.41%
  • Beta0.7327
Data delayed at least 20 minutes, as of Jul 17 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.

  • Revenue in JPY (TTM)6.33bn
  • Net income in JPY-2.90bn
  • Incorporated1946
  • Employees208.00
  • Location
    Taiko Pharmaceutical Co Ltd16F, ORIX Hommachi Bldg1-4-1, Nishihon-machiNishi-kuOSAKA-SHI 550-0005JapanJPN
  • Phone+81 643911110
  • Fax+81 643911199
  • Websitehttps://www.seirogan.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kohjin Bio Co Ltd4.77bn384.98m11.81bn159.0025.043.4717.262.4892.3092.301,122.07666.48------30,000,600.00--------39.44--8.07--1.14--0.4249--0.5715---53.61------
Oncolys Biopharma Inc28.04m-1.98bn12.77bn34.00--7.24--455.30-107.77-107.771.5284.140.01270.000.1476824,647.10-89.46-45.75-101.52-51.86100.0060.46-7,058.44-233.668.82--0.1416---93.54-17.86-68.72--28.18--
ReproCell Inc2.43bn-31.42m13.21bn96.00--1.542,317.405.44-0.3466-0.346628.3493.450.27885.415.6025,279,340.00-0.3609-7.35-0.3932-8.0046.1939.83-1.29-27.1610.54--0.00---17.8317.3989.71--13.27--
RaQualia Pharma Inc2.18bn-253.40m13.81bn67.00--2.30--6.33-11.72-11.72100.79277.210.2472.763.0332,526,720.00-2.872.13-3.182.2688.7088.49-11.635.323.53--0.40310.00-34.8520.62-144.74--0.0967--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn14.23bn109.00--1.98--3.07-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
Stella Pharma Corp269.49m-763.75m14.45bn44.00--5.70--53.63-24.63-24.638.7076.120.06610.05083.986,124,796.00-18.74-22.50-21.00-24.8380.63---283.40-488.655.52-1,319.970.2819--17.65--1.94---5.87--
Ohki Healthcare Holdings Co Ltd334.66bn2.21bn14.55bn632.006.440.50675.810.0435160.45160.4524,293.962,040.702.5613.334.80529,526,900.001.631.857.078.425.146.160.63560.71780.8922--0.199613.929.925.301.281.51-5.345.92
Fuso Pharmaceutical Industries Ltd55.41bn1.38bn22.20bn1.31k14.700.54756.200.4007159.76159.766,434.774,290.490.74743.122.4342,392,500.001.861.913.063.0924.9826.922.492.691.0454.560.257641.108.613.76-14.219.029.13-2.64
Astena Holdings Co Ltd52.63bn1.62bn23.32bn1.40k13.890.78766.060.443140.9840.981,332.61722.460.81273.312.7637,482,540.002.492.494.444.4432.2725.333.062.320.8713--0.351744.924.73-2.85100.61-3.8538.5411.38
TAIKO PHARMACEUTICAL CO LTD6.33bn-2.90bn23.50bn208.00--3.13--3.71-58.49-58.49129.20148.040.4622.043.4430,432,690.00-21.14---26.00--44.27---45.75--2.92--0.2811--21.43--26.23------
StemRIM Inc0.00-2.13bn27.19bn44.00--2.90-----34.87-34.870.00152.360.00----0.00-20.52-6.71-20.87-6.83-------45.8099.90-8,295.360.00--10,128.0663.68108.64------
CellSeed Inc193.68m-892.21m33.58bn35.00--15.00--173.38-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Daito Pharmaceutical Co Ltd46.90bn3.30bn33.74bn1.01k10.220.63126.930.7194210.18210.182,988.733,404.720.63261.892.96--4.296.275.588.2420.9822.656.788.471.11--0.14318.483.982.66-8.47-1.2711.3711.67
Data as of Jul 17 2024. Currency figures normalised to Taiko Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

6.15%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 13 Oct 20231.25m2.47%
Nikko Asset Management Co., Ltd.as of 05 Jul 2024608.20k1.20%
Daiwa Asset Management Co. Ltd.as of 31 May 2024575.10k1.14%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024250.20k0.49%
Norges Bank Investment Managementas of 31 Dec 2023173.00k0.34%
BlackRock Japan Co. Ltd.as of 04 Jul 202480.80k0.16%
Asset Management One Co., Ltd.as of 04 Jul 202461.20k0.12%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 04 Jul 202456.10k0.11%
SSgA Funds Management, Inc.as of 03 Jul 202433.50k0.07%
The Vanguard Group, Inc.as of 31 Oct 202327.03k0.05%
More ▼
Data from 31 Dec 2023 - 11 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.